WHO Regions Define & Classify Biosimilar Medications

JAMA Network

About The Study: This scoping review provides a detailed comparison of biosimilar regulatory guidelines across all World Health Organization regions and identified similarities and differences that may limit the transferability of data between and among countries. These barriers can potentially affect medication availability, price, access, and reimbursement of biosimilars.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.